Usana Health Sciences Inc is a company that specializes in the development and manufacturing of nutritional supplements, personal care products, and energy sports products
Focused on promoting health and well-being, Usana combines science with quality in its offerings, delivering products that support a balanced lifestyle. The company markets its products through a direct selling model, engaging a network of independent distributors to reach consumers globally. Usana is committed to research and innovation, ensuring its formulations meet high standards of efficacy and safety while catering to a diverse range of health and wellness needs.
Health and wellness products company USANA Health Sciences (NYSEUSNA) reported Q4 CY2024 results beating Wall Street’s revenue expectations, but sales fell by 3.4% year on year to $213.6 million. The company’s full-year revenue guidance of $960 million at the midpoint came in 2.7% above analysts’ estimates. Its non-GAAP profit of $0.64 per share was 30.6% above analysts’ consensus estimates.
USANA Health Sciences, Inc. (NYSEUSNA) (the “Company”) today announced financial results for its fiscal fourth quarter and fiscal year ended December 28, 2024. The Company completed the acquisition of a 78.8% controlling ownership stake of Hiya Health Products, LLC (“Hiya”) on December 23, 2024. Consequently, the Company’s fourth quarter and fiscal year 2024 include the effect of less than a week of Hiya’s operating results, which were not significant to the Company’s consolidated results for the same periods. In light of the Hiya acquisition, the Company is now including metrics for Adjusted diluted EPS(1) and Adjusted EBITDA(2). Net earnings, Diluted EPS, Adjusted diluted EPS(1) and Adjusted EBITDA(2) in this press release represent amounts attributable to USANA.
Health and wellness products company USANA Health Sciences (NYSEUSNA)
will be announcing earnings results tomorrow afternoon. Here’s what investors should know.
USANA Health Sciences, Inc. (NYSEUSNA) today announced that fourth quarter and fiscal year 2024 results will be released after the close of market on Tuesday, February 25, 2025. Shortly following the issuance of the Company’s earnings release, the Company will post its Management Commentary document on the Company’s Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, February 26, 2025 at 11:00 a.m. Eastern Time.
USANA Health Sciences, Inc. (NYSEUSNA), a leading developer and manufacturer of high-quality nutritional supplements, healthy foods and personal care products, today announced that Doug Hekking, Chief Financial Officer, will participate in a fireside chat and host one-on-one meetings with investors at the ICR Conference in Orlando, FL on January 13-14, 2025. The fireside chat will begin at 8:00 AM ET on January 13, 2025.
USANA Health Sciences, Inc. (NYSEUSNA) (the “Company,” “USANA”), today announced its acquisition of a 78.8% controlling ownership stake in Hiya Health Products, LLC (“Hiya”), a leading direct-to-consumer provider of high-quality children’s health & wellness products. The $205 million cash transaction closed on December 23, 2024 and is anticipated to be accretive to USANA’s 2025 adjusted EBITDA. For the last twelve months ended September 30, 2024 (unaudited), Hiya generated net sales of $103 million, net income of $19 million, and adjusted EBITDA of $22 million. As of September 30, 2024, Hiya had more than 200,000 customers.
Over the past six months, USANA’s shares (currently trading at $37.74) have posted a disappointing 18.2% loss, well below the S&P 500’s 12.1% gain. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the personal care industry, including USANA (NYSEUSNA) and its peers.
Health and wellness products company USANA Health Sciences (NYSEUSNA) fell short of the market’s revenue expectations in Q3 CY2024, with sales falling 6.2% year on year to $200.2 million. The company’s full-year revenue guidance of $850 million at the midpoint also came in 1.4% below analysts’ estimates. Its GAAP profit of $0.56 per share was 15.5% above analysts’ consensus estimates.
USANA Health Sciences, Inc. (NYSEUSNA) today announced that third quarter 2024 results will be released after the close of market on Tuesday, October 22, 2024. Shortly following the issuance of the Company’s earnings release, the Company will post its Management Commentary document on the Company’s Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, October 23, 2024 at 11:00 a.m. Eastern Time.
USNA stock results show that Usana Health Sciences missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
USANA Health Sciences, Inc. (NYSEUSNA) today announced that second quarter 2024 results will be released after the close of market on Tuesday, July 23, 2024. Shortly following the issuance of the Company’s earnings release, the Company will post its Management Commentary document on the Company’s Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and institutional investors the following morning, Wednesday, July 24, 2024 at 11:00 a.m. Eastern Time.
Study shows no link between daily multivitamin use and lower risk of death in healthy adults. No difference in mortality from cancer, heart disease, or cerebrovascular diseases.
